Other Events. On August 28, 2026, Coherus Oncology, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, through or to the Agent, acting as agent or principal, shares of the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $50.0 million (the “Shares”). The Company is not obligated to sell any Shares under the Sales…

Regulation FD Disclosure. On August 17, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release announcing that the board of directors of the Company declared a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”) and that the Company would make available a document containing answers to certain frequently asked questions about the special dividend (the “FAQ”) on the Investors & Media – Shareholder Services section of the Company’s website. A co…

Termination of a Material Definitive Agreement. ​ As described above, on August 14, 2026, the Company repaid all outstanding amounts due under the Prior Loan Agreement. The Prior Loan Agreement was terminated on the same date and all security interests securing amounts borrowed under the Prior Loan Agreement were released and all obligations of the Company under the Prior Loan Agreement were terminated, except those obligations expressly specified in the Prior Loan Agreement as surviving the…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. ​ See the disclosure set forth above under Item 1.01, which disclosure is incorporated by reference into this

Entry into a Material Definitive Agreement ​ Senior Secured Term Loan ​ On August 12, 2026, Coherus Oncology, Inc. (the “Company”), together with certain wholly owned subsidiaries of the Company (collectively with the Company, the “Borrowers”), entered into a Loan and Security Agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP, as collateral agent (in such capacity, the “Collateral Agent”), and the other lenders signatory thereto (collectively, the “Lenders”), pu…

Other Events. On August 17, 2026, the Company announced a special dividend of CVRs. The CVRs will be distributed on a pro rata basis to stockholders of record of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) as of 5:00 p.m., Eastern Time, on September 30, 2026 (the “Record Date”). One CVR will be issued with respect to each share of Common Stock that is outstanding as of the Record Date. Each CVR represents the right to receive certain potential payments in cash…

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. ​

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with dismissal effective as of such date. The reports of EY on the consolidated financial statements of the Company as of and for the fiscal years en…

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. ​

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. ​

Other Events. ​ On February 12, 2026, Coherus Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc. as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 28,600,000 shares (the “Firm Shares”) of its common stock, par value $0.00…

Other Events. On January 23, 2026, Coherus Oncology, Inc. (the “Company”) filed a prospectus supplement relating to its Sales Agreement, dated November 8, 2022, by and between the Company and Cowen and Company LLC, as amended by the Amendment No. 1 to Sales Agreement, dated May 15, 2023 and Amendment No. 2 to Sales Agreement, dated September 11, 2023, which was assigned to TD Securities (USA) LLC (“TD Cowen”) (the “Sales Agreement”). Pursuant to the Sales Agreement, the Company may offer and…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific referen…

Other Events. Coherus Oncology, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, solely to recast certain financial information and related disclosures included in the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2024 originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2025 (the “2024 Form 10-K”) to provide retrospective discontinued operations presentation for the y…

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. ​

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. ​

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ​ On June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the…

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. ​

Director — Mark D. Stolper: Mr. Stolper decided not to stand for re-election, resulting in his departure from the Board.

Chief Commercial Officer — Paul Reider: Paul Reider resigned as Chief Commercial Officer to pursue other opportunities.

Other Events. ​ On April 1, 2025, the Company issued a press release (the “Press Release”) announcing that it had entered into privately negotiated transactions (the “Repurchases”) with certain holders of its Convertible Notes, pursuant to which the Company agreed to repurchase approximately $170 million aggregate principal amount of the Convertible Notes from such holders at a cash repurchase price equal to 100% of their principal amount, together with the accrued and unpaid interest to, but…

Entry into a Material Definitive Agreement. ​ ​ On March 31, 2025, in connection with the privately negotiated repurchase transactions described in

of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. ​

Other Events ​ ​ On January 28, 2025, Coherus BioSciences, Inc., a Delaware corporation (the “Company”), filed with the U.S. Securities and Exchange Commission (the “SEC”) a definitive proxy statement (the “Proxy Statement”) relating to the special meeting of stockholders (the “Special Meeting”) to be held on March 11, 2025, at 1:30 p.m. Pacific Time, to, among other things, approve the sale of the Company’s UDENYCA (pegfilgrastim-cbqv) franchise (the “Transaction”) to Intas Pharmaceuticals L…

Results of Operations and Financial Condition ​ On January 13, 2025, Coherus BioSciences, Inc. (the “Company”) will present its preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2024 and preliminary unaudited cash, cash equivalents and investments as of December 31, 2024 in a public webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the preliminary financial information included in this presentation is furnished as Exhibit…